HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Neutral rating on Co-Diagnostics (NASDAQ:CODX) and maintained a $2 price target.
June 17, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated its Neutral rating on Co-Diagnostics and maintained a $2 price target, indicating no expected significant short-term movement in the stock price.
The reiteration of a Neutral rating and maintenance of the $2 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This neutral stance typically indicates that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100